INSIGHTS ON DRUG DEVELOPMENT

• Advanced Therapies Going Mainstream: Are We There Yet?

  Advanced therapies are nearing mainstream adoption, with cell, mRNA, and oligonucleotide treatments expanding into broader indications. Learn what’s driving this shift and what manufacturers must do.

• SEDDS: Improving Oral Bioavailability Of Poorly Soluble Compounds

  Nearly 90% of marketed drugs have poor water solubility. Learn how self-emulsifying drug delivery systems (SEDDS) resolve oral bioavailability failures across BCS Class II and IV compounds.

• Flexible Automation For Bioprocess Development And Quality Control

  Flexible lab automation can standardize experimentation across upstream process engineering and downstream quality control, while staying adaptable as process requirements shift.

• Improving Next-Generation Sequencing Workflows With Droplet Digital PCR

  Optimize NGS workflows by using digital PCR for absolute quantification. Improve library quality, reduce bias, and gain sensitive validation for rare variants in complex genomic samples.

• Scale-Up Of AAV Production In Fixed-Bed Bioreactors

  3/31/2026

  Consistent AAV production is critical for manufacturing. See how aligned strategies deliver comparable cell growth, metabolic trends, and rAAV5 titers from development through production.

• History Of Peptides In Medicine: From Early Chemistry To The GLP-1 Era

  4/21/2026

  Peptide therapeutics from early chemical breakthroughs to today’s metabolic drugs, highlighting scientific, clinical, and manufacturing advances shaping modern drug development.

• IP Considerations In Drug Development For Biotech Companies

  4/20/2026

  Integrate a strategic intellectual property approach early in drug development to streamline research, uncover opportunities, and maximize the return on your investment.

• Enabling Flexibility And Scientific Innovation In OSD Development

  8/31/2026

  How one clinical-stage CNS biotech navigated early formulation complexity, shifting pipeline priorities, and scalable manufacturing demands through a strategic CDMO partnership.

• Formulation Strategies For Enabling "Undevelopable" Compounds

  4/29/2025

  KinetiSol enhances bioavailability of poorly soluble drugs like Vemurafenib by producing dense amorphous dispersions, outperforming traditional MBP methods in pharmacokinetics and dissolution.